A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
Public ClinicalTrials.gov record NCT02545543. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population 5 Through 17 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 5 through 17 years of age.
Study identification
- NCT ID
- NCT02545543
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,278 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 5 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2015 (Type not available)
- Primary completion
- Jan 2016 (Actual)
- Completion
- Jun 2016 (Actual)
- Last update posted
- May 23, 2018
2015 – 2016
United States locations
- U.S. sites
- 32
- U.S. states
- 16
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 296 | Huntsville | Alabama | 35802 | — |
| Site 401 | Madera | California | 93637 | — |
| Site 397 | Ontario | California | 91762 | — |
| Site 392 | Redding | California | 96001 | — |
| Site 402 | Sacramento | California | 95822 | — |
| Site 398 | San Jose | California | 95127 | — |
| Site 388 | Hialeah | Florida | 33012 | — |
| Site 293 | Melbourne | Florida | 32934 | — |
| Site 289 | Boise | Idaho | 83642 | — |
| Site 294 | Peoria | Illinois | 61614 | — |
| Site 390 | Augusta | Kansas | 67010 | — |
| Site 396 | Newton | Kansas | 67114 | — |
| Site 400 | Park City | Kansas | 67219 | — |
| Site 317 | Wichita | Kansas | 67207 | — |
| Site 386 | Bardstown | Kentucky | 40004 | — |
| Site 393 | Metairie | Louisiana | 70002 | — |
| Site 287 | St Louis | Missouri | 63141 | — |
| Site 316 | Bellevue | Nebraska | 68005 | — |
| Site 382 | Omaha | Nebraska | 68114 | — |
| Site 285 | Binghamton | New York | 13901 | — |
| Site 387 | Cary | North Carolina | 27511 | — |
| Site 385 | Cincinnati | Ohio | 45246 | — |
| Site 383 | Cleveland | Ohio | 44122 | — |
| Site 399 | Dayton | Ohio | 45414 | — |
| Site 384 | Grove City | Ohio | 43123 | — |
| Site 389 | Gresham | Oregon | 97030 | — |
| Site 283 | Austin | Texas | 78705 | — |
| Site 282 | Fort Worth | Texas | 76135 | — |
| Site 288 | San Angelo | Texas | 76904 | — |
| Site 394 | San Antonio | Texas | 78229 | — |
| Site 395 | Layton | Utah | 84041 | — |
| Site 300 | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02545543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2018 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02545543 live on ClinicalTrials.gov.